Transforming treatment options for people living with type 2 diabetes

Endogenex, in partnership with Mayo Clinic, was founded to revolutionize the therapeutic approach to type 2 diabetes (T2D). Endogenex’s innovations leverage energy delivery in the small intestine (duodenum) to reset the body’s metabolic signaling system, harnessing its’ natural regeneration capabilities to restore metabolic function.

Through the development of the ReCET™ System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D and their ability to regain control of their blood glucose levels.

Based on the principle of resetting the metabolic operating system through energy to eliminate poorly functioning signaling cells, the ReCET System applies the unique capabilities of pulsed electric fields with a novel endoscopic approach. Together, they are intended to restore the natural signaling process of the duodenum, helping the body better control blood glucose levels and potentially slow the progression of type 2 diabetes.

The ReCET Study is a pivotal clinical study evaluating the use of the ReCET System in people living with type 2 diabetes. The ReCET Study will be enrolling participants at clinical sites in the United States and Australia.